Johnson & Johnson is buying RIPTAC developer Halda Therapeutics for 3.05 billion dollars, expanding its prostate cancer pipeline as large drugmakers step up biotech deals in 2025.
Johnson & Johnson said it will acquire Halda Therapeutics, a privately held cancer drug developer based in New Haven, Connecticut, in a 3.05 billion dollar cash deal announced on November 17 2025.
The transaction adds a new precision oncology platform to J&J’s cancer portfolio and supports growth as autoimmune drug Stelara heads into a period of biosimilar competition.
Halda’s lead candidate, HLD-0915, is an oral small molecule for metastatic castration-resistant prostate cancer in a Phase 1/2 trial that began dosing patients in February 2025. The study is listed on ClinicalTrials.gov as NCT06800313, and Halda confirmed first dosing in a company release.
The drug is part of a new class of agents known as regulated induced proximity targeting chimeras, or RIPTAC therapeutics, which link a tumor protein to a pan-essential survival protein to trigger selective cancer cell death. Halda and academic collaborators describe the mechanism in company materials and peer-reviewed work in Cell Chemical Biology.
On October 24 2025, Halda reported first-in-human data showing encouraging safety and anti-tumor activity for HLD-0915 in heavily pretreated prostate cancer patients.
In August 2025, the U.S. Food and Drug Administration granted HLD-0915 fast track designation for metastatic castration-resistant prostate cancer, according to Halda’s news page, which can allow closer FDA interaction and faster review.
Deal terms and J&J strategy
Under the agreement, J&J will pay 3.05 billion dollars in cash for Halda, subject to regulatory approvals and closing conditions. J&J expects the acquisition to close within the next few months and projects about a 15 cent reduction in adjusted 2026 earnings per share from financing costs and equity awards tied to the deal.
The Connecticut biotech drew interest from several major drugmakers, including Novartis, before J&J emerged as the buyer. This is J&J’s second sizable transaction in 2025 after its 14.6 billion dollar takeover of neuroscience group Intra-Cellular Therapies, which closed earlier this year and added antipsychotic drug Caplyta.
What Halda’s RIPTAC platform adds
Halda develops heterobifunctional small molecules that bring together a tumor-specific protein and a survival protein inside cancer cells. Company descriptions and scientific articles explain that this ternary complex blocks the survival protein in cancer cells while largely sparing healthy tissue.
Beyond HLD-0915, Halda lists preclinical programs for breast, lung and p53-mutant tumors on its pipeline page.
The company has raised more than 200 million dollars to support this work, including a 126 million dollar Series B extension announced in August 2024.
In August 2025, Halda also entered an AI-enabled discovery alliance with VantAI that can deliver more than 1 billion dollars in potential payments to the partner across multiple programs.
Biotech deal flow stays active in 2025
Data from tracker DealForma, show at least 23 pharmaceutical acquisitions between 1 billion and 10 billion dollars so far in 2025, pointing to a busy year for mid-sized biotech transactions.
Analysts link this activity to looming patent expiries on blockbuster medicines and a push by large drugmakers to add new cancer and neuroscience assets, a trend reflected in J&J’s recent deals as well as transactions by several peers.
Disclaimer
For paid/sponsored articles, FintechMode neither endorses nor takes responsibility for the accuracy, timeliness, quality, and content of said articles. The statements, views and opinions expressed in paid/sponsored articles are solely those of the content provider and readers are reminded that Cryptocurrency products are unregulated in most locations and can be highly risky. Do your own research and consult relevant financial experts before making any investment decisions. FintechMode will not be held accountable, either directly or indirectly, for any harm or loss that may stem from or be linked to the usage or reliance on any information, goods, or services mentioned on this page. If you have any concerns, please email [email protected] or refer to our Terms & Conditions
